{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12"],"submitter":["Macias-Parra M"],"pubmed_abstract":["<h4>Introduction</h4>Rotavirus-associated diarrheal diseases significantly burden healthcare systems, particularly affecting infants under five years. Both Rotarix™ (RV1) and RotaTeq™ (RV5) vaccines have been effective but have distinct application schedules and limited interchangeability data. This study aims to provide evidence on the immunogenicity, reactogenicity, and safety of mixed RV1-RV5 schedules compared to their standard counterparts.<h4>Methods</h4>This randomized, double-blind study evaluated the non-inferiority in terms of immunogenicity of mixed rotavirus vaccine schedules compared to standard RV1 and RV5 schedules in a cohort of 1,498 healthy infants aged 6 to 10 weeks. Participants were randomly assigned to one of seven groups receiving various combinations of RV1, and RV5"],"journal":["Frontiers in public health"],"pagination":["1356932"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10920348"],"repository":["biostudies-literature"],"pubmed_title":["Immunogenicity of RV1 and RV5 vaccines administered in standard and interchangeable mixed schedules: a randomized, double-blind, non-inferiority clinical trial in Mexican infants."],"pmcid":["PMC10920348"],"pubmed_authors":["Richardson VL","Rodriguez-Weber MA","Moreno-Macias H","Reyna-Figueroa J","Fortes-Gutierrez S","Hernandez-Benavides I","Vazquez-Cardenas P","Macias-Parra M","Vidal-Vazquez P"],"additional_accession":[]},"is_claimable":false,"name":"Immunogenicity of RV1 and RV5 vaccines administered in standard and interchangeable mixed schedules: a randomized, double-blind, non-inferiority clinical trial in Mexican infants.","description":"<h4>Introduction</h4>Rotavirus-associated diarrheal diseases significantly burden healthcare systems, particularly affecting infants under five years. Both Rotarix™ (RV1) and RotaTeq™ (RV5) vaccines have been effective but have distinct application schedules and limited interchangeability data. This study aims to provide evidence on the immunogenicity, reactogenicity, and safety of mixed RV1-RV5 schedules compared to their standard counterparts.<h4>Methods</h4>This randomized, double-blind study evaluated the non-inferiority in terms of immunogenicity of mixed rotavirus vaccine schedules compared to standard RV1 and RV5 schedules in a cohort of 1,498 healthy infants aged 6 to 10 weeks. Participants were randomly assigned to one of seven groups receiving various combinations of RV1, and RV5","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2026-07-15T07:50:58.409Z","creation":"2024-11-20T19:06:30.436Z"},"accession":"S-EPMC10920348","cross_references":{"pubmed":["38463163"],"doi":["10.3389/fpubh.2024.1356932"]}}